AWM
RAPT

Avior Wealth Management’s RAPT Therapeutics RAPT Stock Holding History

Avior Wealth Management’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1
Closed -$62 – 3381
2024
Q1 		$62 Buy
+1
New +$139 ﹤0.01% 3396

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Avior Wealth Management's RAPT Position: Q2 2024 in Review

Avior Wealth Management sold out of RAPT Therapeutics (RAPT) in Q2 2024, closing a stake of 1 share — an estimated $62 sold.

Avior Wealth Management first reported a position in RAPT in Q1 2024 and held it in 1 quarter. The position peaked at $62 in Q1 2024. 103 funds tracked by Wall St. Rank hold RAPT as of Q2 2024.

  • Avior Wealth Management reported no remaining RAPT Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 1 RAPT Therapeutics share in Q2 2024, an estimated $62.
  • Avior Wealth Management first reported a position in RAPT Therapeutics in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's RAPT Therapeutics position peaked at $62 in Q1 2024.
  • 103 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.